Moretus Research offers cutting-edge buy-side quality equity research to serious investors seeking clarity, convictions and alpha. Focusing on the US open market, Moretus applies a structured, repeatable framework to identify companies with durable business models, potential for false price cash flows, and intelligent capital allocations. Building on institutional standards, Moretus Research combines rigorous basic analysis with a high-ranking judgment-driven process, including noise, narrative and overly complex predictions. The assessment is based on practical, sector-related multiples tailored to each company’s business model and capital structure, with an emphasis on comparability, simplicity, and relevance. Research coverage tends to support underrated companies that have undergone structural changes or temporary dislocations. This is when calm analysis and perception of variants can lead to asymmetric returns. All work reflects deep respect for capital, discipline and long-term compounding. Moretus Research aims to raise the standards for independent investment research. This is to provide a powerful filter of professional grade insights, practical valuations, and what’s really important in modern stock analysis.
Analyst Disclosure: I/We have no inventory, options, or similar derivative positions in any of the companies mentioned, and we have no plans to start such positions within the next 72 hours. I wrote this article myself and it represents my own opinion. I have not received compensation for it (other than asking for alpha). There is no business relationship with the companies mentioned in this article.
We are seeking disclosure of alpha: Past performance does not guarantee future results. No recommendations or advice is provided as to whether an investment is suitable for a particular investor. The above views and opinions may not reflect what we ask for alpha in general. It is not a licensed securities dealer, broker, or US investment advisor or investment bank to seek Alpha. Our analysts are third party authors that include both professional and individual investors who may not be licensed or accredited by the lab or regulatory body.
